Compare KNSA & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNSA | QLYS |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2018 | 2012 |
| Metric | KNSA | QLYS |
|---|---|---|
| Price | $47.48 | $93.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 15 |
| Target Price | $53.71 | ★ $138.07 |
| AVG Volume (30 Days) | 445.1K | ★ 663.7K |
| Earning Date | 04-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.38 |
| EPS | 0.57 | ★ 3.97 |
| Revenue | ★ $423,239,000.00 | $321,607,000.00 |
| Revenue This Year | $62.99 | $9.89 |
| Revenue Next Year | $33.30 | $6.96 |
| P/E Ratio | $82.68 | ★ $25.98 |
| Revenue Growth | ★ 56.60 | 15.32 |
| 52 Week Low | $18.26 | $101.61 |
| 52 Week High | $47.51 | $155.47 |
| Indicator | KNSA | QLYS |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 26.33 |
| Support Level | $43.55 | $101.61 |
| Resistance Level | $47.51 | $114.34 |
| Average True Range (ATR) | 1.67 | 6.23 |
| MACD | 0.26 | -1.39 |
| Stochastic Oscillator | 95.93 | 7.18 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.